Predictive value of serum HER2/neu ECD during trastuzumab-based therapy in patients with breast cancer

MLA

Ko¨stler, W. J., et al. “Predictive Value of Serum HER2/Neu ECD during Trastuzumab-Based Therapy in Patients with Breast Cancer.” European Journal of Cancer, vol. 38, no. 1, Jan. 2002, p. S109. EBSCOhost, https://doi.org/10.1016/S0959-8049(02)80349-5.

APA

Ko¨stler, W. J., Schwab, B., Singer, C. F., Neumann, R., Marton, E., Brodowicz, T., Steger, G., Wiltschke, C., Krainer, M., & Zielinksi, C. C. (2002). Predictive value of serum HER2/neu ECD during trastuzumab-based therapy in patients with breast cancer. European Journal of Cancer, 38(1), S109. https://doi.org/10.1016/S0959-8049(02)80349-5

Chicago

Ko¨stler, W.J., B. Schwab, C.F. Singer, R. Neumann, E. Marton, T. Brodowicz, G. Steger, C. Wiltschke, M. Krainer, and C.C. Zielinksi. 2002. “Predictive Value of Serum HER2/Neu ECD during Trastuzumab-Based Therapy in Patients with Breast Cancer.” European Journal of Cancer 38 (1): S109. doi:10.1016/S0959-8049(02)80349-5.